FDA approves new painkiller that shows promise and challenges of opioid alternatives
The U.S. Food and Drug Administration said it approved Vertex Pharmaceuticals’ Journavx for short-term pain that often ...
New Pain Drug Gets FDA Nod as Safer Alternative to Addictive Opioids
Vertex Pharmaceuticals Inc. gained US approval for the first new type of painkiller in more than two decades, paving the way ...
US FDA approves Axsome Therapeutics' migraine drug
The U.S. Food and Drug Administration has approved Axsome Therapeutics' migraine treatment, the company said on Thursday.
FDA Approves the First Non-Opioid Pain Drug in 20 Years
The prescription pills, sold under the brand name Journavx and made by Vertex Pharmaceuticals, are taken twice a day and ...
F.D.A. Approves Drug to Treat Pain Without Opioid Effects
The drug, Journavx by Vertex Pharmaceuticals, blocks pain signals to the brain, making it nonaddictive. The Food and Drug ...
Do food warning labels actually work? Answering your questions.
Readers had a lot to say about my latest column on the Food and Drug Administration’s proposed front-of-package labels. Most ...
Americans might finally have to face what’s in their food
A front-of-package food label would be a great educational tool. The Trump administration should keep it.
As Trump and RFK Jr. move to upend drug making, Seattle biotech bets on science
Robert F. Kennedy Jr. may soon be America's top pharmaceutical regulator. That is cause for concern in Seattle’s biotech ...
Recalled potato chips sold in Oregon and Washington could cause ‘serious adverse health consequences’
The Food and Drug Administration has newly classified the December recall of some Lay’s Classic Potato Chips sold in Oregon ...
Editorial: Not all ‘processed’ food is bad — but Red Dye No. 3 and harmful chemicals don’t belong in what we eat
While food alone can’t be blamed, it’s certainly part of the problem. The European Union has banned a number of ingredients ...
BioPharma Dive13h
Vertex’s non-opioid pain drug gets FDA approval in milestone for company and research
Despite high demand for an option like Journavx, doctors fear the drug’s price could be a major hangup for insurers, ...